Please use this identifier to cite or link to this item: http://cmuir.cmu.ac.th/jspui/handle/6653943832/51031
Full metadata record
DC FieldValueLanguage
dc.contributor.authorS. Saokaewen_US
dc.contributor.authorU. Permsuwanen_US
dc.contributor.authorN. Chaiyakunapruken_US
dc.contributor.authorS. Nathisuwanen_US
dc.contributor.authorA. Sukonthasarnen_US
dc.date.accessioned2018-09-04T04:50:24Z-
dc.date.available2018-09-04T04:50:24Z-
dc.date.issued2010-11-01en_US
dc.identifier.issn15387836en_US
dc.identifier.issn15387933en_US
dc.identifier.other2-s2.0-78149244834en_US
dc.identifier.other10.1111/j.1538-7836.2010.04051.xen_US
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=78149244834&origin=inwarden_US
dc.identifier.urihttp://cmuir.cmu.ac.th/jspui/handle/6653943832/51031-
dc.description.abstractObjective: Although pharmacist-participated warfarin therapy management (PWTM) has been accepted and implemented in various parts of the world, the evidence demonstrating the effects of PWTM compared with usual care on clinical outcomes is lacking. We performed a systematic review and meta-analysis to compare the effects of PWTM with usual care on bleeding and thromboembolic outcomes. Methods: We searched MEDLINE, SCOPUS, EMBASE, IPA, CINAHL, Cochrane CENTRAL, Thai Index Medicus and Thai Medical Index, and reference lists of studies, without language restriction. Databases were searched from their inception to July 2009. The studies using warfarin as an anticoagulant with sufficient data for compilation of 2 × 2 tables were included. Both randomized controlled trials (RCTs) and non-RCTs were considered. Two authors independently reviewed each study, assigned quality scores and extracted data for all outcomes using a standardized form. Pooled effect estimates (risk ratio; RR) were obtained using a random effects model. Result: Of 661 articles identified, 24 studies with 728,377 patients were included. In the random-effects meta-analysis of RCTs, the PWTM group had statistically significant effects on the prevention of total bleeding [RR, 0.51; 95% confidence interval (CI), 0.28-0.94]. However, the effects on major bleeding (RR, 0.64; 95% CI, 0.18-2.36), thromboembolic events (RR, 0.79; 95% CI, 0.33-1.93), all-cause mortality (RR, 0.93; 95% CI, 0.41-2.13) and warfarin-related mortality (RR, 0.65; 95% CI, 0.18-2.42) were not significant. Conclusion: Pharmacist's participation in the management of warfarin therapy significantly reduces total bleeding, with a non-significant trend towards decreases in other warfarin-related complications. © 2010 International Society on Thrombosis and Haemostasis.en_US
dc.subjectMedicineen_US
dc.titleEffectiveness of pharmacist-participated warfarin therapy management: A systematic review and meta-analysisen_US
dc.typeJournalen_US
article.title.sourcetitleJournal of Thrombosis and Haemostasisen_US
article.volume8en_US
article.stream.affiliationsChiang Mai Universityen_US
article.stream.affiliationsNaresuan Universityen_US
article.stream.affiliationsUniversity of Queenslanden_US
article.stream.affiliationsUniversity of Wisconsin Madisonen_US
article.stream.affiliationsMahidol Universityen_US
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.


Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.